


Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.



NED = no evidence of disease

¹ **Category 1:** Localized, Stages I – III

Category 2: Metastatic, Stage IV

² Consider checking CEA for a total of 10 years only

³ The recommended screening intervals for individuals with adenomatous polyps on most recent colonoscopy, genetic predisposition to colon cancer, or a history of inflammatory bowel disease can be found in the [Colorectal Cancer Screening algorithm](#)


Note: Clinical risk is based on preoperative staging (clinical stage) vs. pathologic staging, which is based on the post-operative tumor specimen (for patients that were unable to receive neoadjuvant therapy)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

ELIGIBILITY

CONCURRENT COMPONENTS OF VISIT

DISPOSITION



NED = no evidence of disease

¹ See [Physical Activity, Nutrition](#), and [Tobacco Cessation](#) algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice

² Includes [breast](#), [cervical](#) (if appropriate), [liver](#), [lung](#), [pancreatic](#), [prostate](#), and [skin cancer screening](#)

³ Consider use of Vanderbilt's [ABCDE's approach to cardiovascular health](#)

⁴ Based on [Centers for Disease Control and Prevention \(CDC\) guidelines](#)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS

- Baca, B., Beart Jr, R. W., & Etzioni, D. A. (2011). Surveillance after colorectal cancer resection: A systematic review. *Diseases of the Colon and Rectum*, 54(8), 1036-1048. doi:10.1007/DCR.0b013e31820db364
- Bailey, C. E., Tran Cao, H. S., Hu, C. Y., Chang, G. J., Feig, B. W., Rodriguez-Bigas, M. A., ... You, Y. N. (2015). Functional deficits and symptoms of long-term survivors of colorectal cancer treated by multimodality therapy differ by age at diagnosis. *Journal of Gastrointestinal Surgery*, 19(1), 180-188. doi:10.1007/s11605-014-2645-7
- Centers for Disease Control and Prevention. (2018). *Recommended immunization schedule for adults aged 19 years or older, United States, 2018*. Retrieved from <https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html>
- Chang, G. J. & Ninan, T. (2018). Colorectal cancer survivorship care. In M. A. Rodriguez, & L. E. Foxhall (Eds.), *Handbook of cancer survivorship care* (pp.125-138). New York: Springer Publishing Company.
- El-Shami, K., Oeffinger, K. C., Erb, N. L., Willis, A., Bretsch, J. K., Pratt-Chapman, M. L., ... Cowens-Alvarado, R. L. (2015). American Cancer Society colorectal cancer survivorship care guidelines. *CA: A Cancer Journal for Clinicians*, 65(6), 428-455. doi:10.3322/caac.21286
- Kim, T. H., Chang, H. J., Kim, D. Y., Jung, K. H., Hong, Y. S., Kim, S. Y., ... Jeong, S. Y. (2010). Pathologic nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. *International Journal of Radiation Oncology, Biology, Physics*, 77(4), 1158-1165. doi:10.1016/j.ijrobp.2009.06.019
- Kobayashi, H., Mochizuki, H., Morita, T., Kotake, K., Teramoto, T., Kameoka, S., ... Sugihara, K. (2009). Timing of relapse and outcome after curative resection for colorectal cancer: a Japanese multicenter study. *Digestive Surgery*, 26(3), 249-255. doi:10.1159/000226868
- Lange, M., Marijnen, C. A. M., Maas, C. P., Putter, H., Rutten, H. J., Stiggelbout, A. M., ... Cooperative Clinical Investigators of the Dutch. (2009). Risk factors for sexual dysfunction after rectal cancer treatment. *European Journal of Cancer*, 45(9), 1578-1588. doi:10.1016/j.ejca.2008.12.014
- National Comprehensive Cancer Network. (2019). *Rectal cancer* (NCCN Guidelines Version 2.2019). Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf
- Ode, K., Patel, U., Virgo, K. S., Audisio, R. A., & Johnson, F. E. (2009). How initial tumor stage affects rectal cancer patient follow-up. *Oncology Reports*, 21(6), 1511-1517. https://doi.org/10.3892/or_00000382
- Park, J., Neuman, H. B., Weiser, M. R., & Wong, W. D. (2010). Randomized clinical trials in rectal and anal cancers. *Surgical oncology clinics of North America*, 19(1), 205-223. doi:10.1016/j.soc.2009.09.005
- Park, I. J., You, Y. N., Agarwal, A., Skibber, J. M., Rodriguez-Bigas, M. A., Eng, C., ... Chang, G. J. (2012). Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. *Journal of Clinical Oncology*, 30(15), 1770-1776. doi:10.1200/JCO.2011.39.7901
- Simard, J., Kamath, S., & Kircher, S. (2019). Survivorship guidance for patients with colorectal cancer. *Current Treatment Options in Oncology*, 20(5), 38. doi:10.1007/s11864-019-0635-4
- Snyder, R. A., Hu, C. Y., Cuddy, A., Francescatti, A. B., Schumacher, J. R., Van Loon, K., ... Chang, G. J. (2018). Association between intensity of posttreatment surveillance testing and detection of recurrence in patients with colorectal cancer. *JAMA*, 319(20), 2104-2115. doi:10.1001/jama.2018.5816
- Steele, S. R., Chang, G. J., Hendren, S., Weiser, M., Irani, J., Buie, W. D., & Rafferty, J. F. (2015). Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer. *Diseases of the Colon & Rectum*, 58(8), 713-725. doi:10.1097/DCR.0000000000000410
- Thong, M. S. Y., Wolschon, E.-M., Koch-Gallenkamp, L., Waldmann, A., Waldeyer-Sauerland, M., Pritzkeleit, R., ... Arndt, V. (2018). "Still a cancer patient" - associations of cancer identity with patient-reported outcomes and health care use among cancer survivors. *JNCI Cancer Spectrum*, 2(2), 1-9. doi:10.1093/jncics/pky031

Continued on next page

Disclaimer: *This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.*

SUGGESTED READINGS - continued

Vanderbilt Cardio-Oncology Program. (2017). *Know Your ABCDE's*. Retrieved from <http://www.cardioonc.org/2017/08/29/know-your-abcs/>

Wille-Jorgensen, P., Syk, I., Smedh, K., Laurberg, S., Nielsen, D. T., Peterson, S. H., ... Sorensen, H. T. (2018). Effects of more vs less frequent follow-up testing on overall and colorectal cancer-specific mortality in patients with stage II or III colorectal cancer: The COLOFOL randomized clinical trial. *JAMA*, 319(20), 2095-2103. doi:10.1001/jama.2018.5623

You, Y. N., Habiba, H., Chang, G. J., Rodriguez-bigas, M. A., & Skibber, J. M. (2011). Prognostic value of quality of life and pain in patients with locally recurrent rectal cancer. *Annals of Surgical Oncology*, 18(4), 989-996. doi:10.1245/s10434-010-1218-6

Disclaimer: *This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.*

DEVELOPMENT CREDITS

This survivorship algorithm is based on majority expert opinion of the Colorectal Survivorship work group at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Therese B. Bevers, MD (Cancer Prevention)
George J. Chang, MD, MS (Surgical Oncology)
Elise Cook, MD (Clinical Cancer Prevention)
Robin Coyne, APRN, FNP-BC (Cancer Prevention)
Joyce Dains, DrPH, APRN, FNP-BC (Department of Nursing)
Prajnan Das, MD (Radiation Oncology)
Katherine Gilmore, BA, MPH (Cancer Survivorship)
Thoa Kazantsev, BSN, RN, OCN[♦]
Scott Kopetz, MD (GI Medical Oncology)
Marita Lazzaro, APRN, ANP-BC (Cancer Prevention)
Tiffany McGowan, MS, RN, FNP (Cancer Prevention)
Ana Nelson, APRN, FNP-BC (Cancer Prevention)
Lonzetta Newman, MD (Cancer Prevention)
Tilu Ninan, APRN, ANP-BC (Cancer Prevention)

[♦] Clinical Effectiveness Development Team